Health Kick Podcast: Fresh data keeps Neurizon on track in ALS fight

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast.

In this episode, Tim catches up with Neurizon Therapeutics (ASX:NUZ) managing director and CEO Dr Michael Thurn for an update on the company’s ALS program and its lead candidate, NUZ-001.

Neurizon believes it has resolved the FDA’s concerns behind a clinical hold with new safety data, yet with the review process delayed the company remains hopeful of advancing to a pivotal Phase 2/3 trial on the Healy ALS Platform.

Dr Thurn explains what the hold means, how patient advocacy groups are stepping in, and why new data showing NUZ-001 may extend survival and slow disease progression has the company confident of a breakthrough.

Tune into the podcast to hear more.

This podcast was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.